 NEW YORK, July 06, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics LLC NYSE American: BTX Brooklyn or the Company, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on June 21 2021, Sandra M. Gurrola was granted a restricted stock unit grant covering 35,000 shares of Brooklyns common stock the Gurrola RSU, and that on June 28, 2021, Kevin A. DAmour was granted a non-qualified stock option covering 140,580 shares of Brooklyns common stock the Time-Based Option and a restricted stock unit covering 70,290 shares of Brooklyns common stock the DAmour RSU. 